buserelin + tamoxifen

Buserelin + tamoxifen is a combination therapy used in the treatment of breast cancer, particularly in premenopausal patients with metastatic breast cancer. Buserelin is a luteinizing hormone-releasing hormone (LHRH) agonist that suppresses estrogen production, while tamoxifen is an anti-estrogen that blocks estrogen receptors. The combination has shown varying efficacy in clinical studies, with some research indicating improved overall survival compared to either drug alone in premenopausal metastatic breast cancer patients, while other studies suggest that the combination might be less effective than single agents in certain contexts.